Cargando…

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL

Detalles Bibliográficos
Autores principales:	Zinzani, P. L., Özcan, M., Sapunarova, K., Jurczak, W., Hamed, A., Bouabdallah, K., Saydam, G., Geissler, K., Szomor, Á., Lazaroiu, M., Salar, A., Tempescul, A., Nalcaci, M., Gercheva, L., Egyed, M., Panayiotidis, P., Mongay Soler, L., Cao, A., Phelps, C., H Childs, B., J Matasar, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429570/ http://dx.doi.org/10.1097/01.HS9.0000847420.24995.43

Ejemplares similares

Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab
por: Morcos, Peter N., et al.
Publicado: (2023)

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
por: Matasar, Matthew J., et al.
Publicado: (2021)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
por: de Vos, S, et al.
Publicado: (2018)

Use of Rituximab in NHL Malt Type Pregnant in I° Trimester for Two Times
por: Sica, Antonello, et al.
Publicado: (2019)

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
por: Graf, Solomon A., et al.
Publicado: (2022)

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
por: Doorduijn, J., et al.
Publicado: (2022)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023)

The chronos principle
por: Christodoulou, D M
Publicado: (1974)

PB2132: COPANLISIB PLUS RITUXIMAB-BENDAMUSTINE FOR RELAPSED-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RECRUITMENT UPDATE ON AN ONGOING PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL_COPA-RB)
por: Novo, M., et al.
Publicado: (2022)

Physicochemical Evaluation of Lyophilized Formulation of p-SCN-Bn-DOTA- and p-SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy
por: Ackova, Darinka Gjorgieva, et al.
Publicado: (2016)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

The effect of Rituximab treatment on T cells
por: Diaz-Torné, C, et al.
Publicado: (2010)

Rituximab
por: Tridente, Giuseppe
Publicado: (2013)

Rituximab: mechanisms and applications
por: Johnson, P W M, et al.
Publicado: (2001)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
por: Zinzani, P. L., et al.
Publicado: (2022)

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
por: Dreyling, M., et al.
Publicado: (2017)

Biosimilars Have Arrived: Rituximab
por: Greenwald, Maria, et al.
Publicado: (2018)

Rituximab therapy in Greek patients with rheumatoid arthritis
por: Tsiakalos, Aristotelis P, et al.
Publicado: (2008)

Rituximab in kidney disease and transplant
por: Chauhan, Kajal, et al.
Publicado: (2019)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Successful Treatment of Cryoglobulinaemia with Rituximab
por: Choudhry, M., et al.
Publicado: (2012)

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2019)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

Rituximab in the Treatment of Pemphigus Vulgaris
por: Zakka, Labib R., et al.
Publicado: (2012)

Rituximab in early systemic sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2017)

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
por: Thurlings, R M, et al.
Publicado: (2008)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Update on the role of copanlisib in hematologic malignancies
por: Le, Thuy, et al.
Publicado: (2021)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
por: Haujir, A., et al.
Publicado: (2022)

Rituximab-Related Reversible Hepatocellular Damage
por: Toprak, Selami K., et al.
Publicado: (2012)

Relationship between NK Cell Activation and Clinical Response in Rheumatoid Arthritis Treated with Rituximab
por: Lurati, A., et al.
Publicado: (2009)

Rituximab Dosing in Glomerular Diseases: A Scoping Review
por: Alzayer, Husam, et al.
Publicado: (2022)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

Clinical use of rituximab in haematological malignancies
por: Avivi, I, et al.
Publicado: (2003)

Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases
por: Hindilerden, Fehmi, et al.
Publicado: (2017)

Comparison of Response to Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia According to the Presence of Accessory Spleen
por: Hindilerden, Fehmi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7r50qiff72oh994m7ibahsnts6